Comparing the Efficacy of Tolterodine and Gabapentin Versus Placebo in Catheter Related Bladder Discomfort after Percutaneous Nephrolithotomy: A Randomized Clinical Trial by Maghsoudi, R. et al.
Comparing the Efficacy of Tolterodine and Gabapentin
Versus Placebo in Catheter Related Bladder Discomfort
After Percutaneous Nephrolithotomy:
A Randomized Clinical Trial
Robab Maghsoudi, MD,1 Saeed Farhadi-Niaki, MD,1 Masoud Etemadian,1 MD,
Amir H Kashi,1 MD, Pejman Shadpour, MD,2 Asemaneh Shirani, MD,1
Rana Samadinezhad-Khoshbaf-Sorkhabi, BS,1 and Meghdad Tabatabaei, MD1
Abstract
Purpose: The purpose of this study was to compare the efficacy of tolterodine and gabapentin vs placebo in
catheter related bladder discomfort (CRBD) following percutaneous nephrolithotomy (PCNL).
Materials and Methods: This study was a double-blind parallel group randomized clinical trial. Patients who
were candidates of PCNL were enrolled. Patients were randomized to treatment groups of tolterodine 2mg orally
(PO) (group T, n= 50), gabapentin 600mg PO (group G, n= 50), and placebo (group P, n= 70) 1 hour before
operation using balanced block randomization. The primary endpoint of interest was visual analog pain scale in 1,
3, 12, and 24 hours after the operation. Secondary endpoints included rescue analgesic use (opioid and nonopioid).
Results: The frequency of severe CRBD in 1,12, and 24 hours after the operation was 4%, 4%, and 6% in group
T vs 4%, 0%, and 2% in group G vs 47%, 14%, and 6% in the P group ( p < 0.001). The number of paracetamol
injections for CRBD in the T and G groups was significantly lower than the placebo group (1.8– 0.8 vs 1.8– 0.7
vs 3.6– 0.7, p< 0.001). Likewise the number of pethidine injections in the T and G groups was significantly
lower than the placebo group (0.42 – 0.54 vs 0.68 – 0.62 vs 2.4– 0.64, p< 0.001). In patients with history of
Double-J insertion, the severity of CRBD was lower in all treatment groups.
Conclusions: Preoperative administration of oral tolterodine or gabapentin reduces postoperative CRBD and
the need for rescue analgesics as much as 24 hours after surgery. Patients with history of Double-J insertion
experience less CRBD.
Keywords: pain measurement, tolterodine, gabapentin, percutaneous nephrolithotomy, catheter related bladder
discomfort
Introduction
W ith the increasing desire of early discharge fol-lowing surgery and performing minimally invasive
procedures, pain management after catheterization following
surgery has become an important issue.1,2 Catheter related
bladder discomfort (CRBD) manifests itself by spontaneous
contractions in the detrusor due to physical stimulation of the
catheter.1–4 Elsewhere CRBD can also present with a sen-
sation to urinate or discomfort in the suprapubic area, which
in turn can lead to increasing postoperative pain and decrease
of the quality of life.2–6 Prevalence of discomfort is reported
at 60% which following treatment is reduced to 25%.2 Dif-
ferent medications, including antimuscarinic agents, antiepi-
leptic agents, analgesics, and narcotics, have been used to treat
CRBD. Tolterodine and gabapentin are two of the common
medications for CRBD treatment.
CRBD is thought to occur as a result of bladder muscular
contractions due to activation of bladder muscarinic receptors.
Antimuscarinic agents such as tolterodine and oxybutynin are
competing antagonists of the bladders’muscarinic receptors and
adjust the overstimulation of the sacral reflex center. Therefore,
these agents had been the mainstay of CRBD treatment.
Gabapentin is derived from gamma-Aminobutyric acid and
reduces the release of glutamate.Glutamate is a neurotransmitter
which transfers pain to the central nervous system. It attaches
to the a2d1 and 2 subunit in voltage gated calcium channels
and reduces the flow of calcium in the central nervous system.
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Gabapentin also stops new synapses from being formed. It has
been observed that the upregulation of afferent fibers (C-fibers)
in the bladder is the cause of lower urinary tract symptoms such
as urgency and frequency. Gabapentin inhibits the C-fibers and
based on its safety and efficiency is a suitable choice for lower
urinary tract symptoms. The efficacy of gabapentin in overactive
bladder refractory to anticholinergic medications has also been
demonstrated.7
Most previous studies evaluated medications within the
same classification, including antimuscarinic agents2,8–12 and
antiepileptic agents5,7,13 on CRBD. A recent review article on
treatments for CRBD emphasized the need for direct com-
parisons between medications of different classifications.14
The purpose of this study was to perform a direct head to
head comparison for evaluation of the efficacy of tolterodine
vs gabapentin vs placebo in CRBD following percutaneous
nephrolithotomy (PCNL).
Materials and Methods
This study is a parallel group randomized clinical trial.
Patients who were referred to our center for PCNL operation
from March 2016 to December 2016 were included. Inclu-
sion criteria for PCNL were as follows: renal stones ‡2 cm on
longest diameter, smaller stones resistant to extracorporeal
shockwave lithotripsy, large proximal ureteral stones, age
‡18 years, and American Society of Anesthesiology score of
I (no prior history of acute or chronic illnesses, including
malignancies, systemic diseases, chronic infections, and age
£60 years). Exclusion criteria were as follows: drug or al-
cohol abuse, allergic reactions to gabapentin, tolterodine or
narcotics, painful circumstances which can affect pain as-
sessment, including lower urinary tract symptoms, medical or
psychologic circumstances which can affect the patients’
communication or tolerance, analgesic use within 12 hours
before surgery, urethral pathologies necessitating interven-
tion or causing difficulty in passage of urethral catheter, and
change in anesthesia protocol during the operation.
All patients were admitted the day before surgery. Laboratory
examinations included complete blood count, creatinine, as-
partate transferase, alanine transferase, prothrombin time, partial
thromboplastin time, and direct and indirect bilirubin. Patients
were randomly allocated to groups of tolterodine (n= 50), ga-
bapentin (n= 50), and placebo (n= 70) using balanced block
randomization. The allocated treatments of each patient were
recorded in concealed envelopes designated as A, B, or C and
were opened after ensuring eligibility. Information regarding
visual analog pain reportingwas given to each patient by a staff
nurse before surgery, and the designateddrugwas administered
according to envelope contents. Envelope A patients were gi-
ven oral tolterodine 2mg with a sip of water 1 hour before
surgery (designated as group T afterward). EnvelopeB patients
were administered oral gabapentin 600mg with a sip of water
1 hour before surgery (designated as group G afterward). En-
velopeCpatientswere given oral vitaminC (250mg)with a sip
of water 1 hour before surgery (designated as group P after-
ward). Patients were unaware of the type of medications they
received.
Surgical methods
The anesthesia protocol was the same for each patient:
Atracurium with a dose of 0.5 to 0.6mg/kg, fentanyl 5 to
10mg/kg, Nesdonal 5 to 7mg/kg, and inhalation isoflurane
MAC = 0.8 to 1. After extubation, no drug was used in the
protocol. In case of need for change of anesthesia protocol,
the patient was excluded from the study.
PCNL operation was performed according to the stan-
dard prone position with fluoroscopic guidance as described
earlier15,16 and is summarized below. After cystoscopy a
5F ureteral catheter was fixed to 16F urethral catheter. The
urethral catheter was inserted after passing lubricating lido-
caine jelly into the urethra and its balloon was filled with
10mL sterile water. If the insertion of ureteral catheter was
not possible through cystoscope, it was inserted by use of
ureteroscope. Access was obtained in prone position under
fluoroscopic guidance, and the tract was dilated to 30F by
single shot Amplatz dilators. Lithotripsy was accomplished
using pneumatic lithotripter. The procedure was typically
terminated leaving an internal (Double-J) or external ureteral
catheter in place. The 16F urethral catheter, which was in-
serted after cystoscopy, was fixed with adhesive tapes to the
suprapubic area.
Outcome measurement
The primary endpoint of interest was visual analog pain
scale (VAS) which was measured 1, 3, 12, and 24 hours after
surgery by staff nurses. The nurses who measured VAS were
blinded to treatment allocations of patients. VAS scores were
graded as follows: 0, no pain; 1 to 4, mild pain; 5 to 7,
moderate pain; and ‡8, severe pain based on the average
finding of previous studies.17–20
Secondary endpoints included the number of injections
of non-narcotic agents (paracetamol) and narcotic agents
(pethidine 25mg). These rescue analgesics were given to
patients with moderate-to-severe VAS (VAS score >4).
In the postoperative period, vital signs, including temper-
ature, blood pressure, heart rate, and respiratory rate, were
recorded at 1, 3, 12, and 24 hours after operation.
Statistical analysis
Data were entered into the SPSS ver. 21 software for
analysis. The statistician was aware of the existence of 3
distinct study groups, but was unaware of their specifications.
Comparison of quantitative variables over three study groups
was performed with one way analysis of variance. Qualitative
variables were compared using chi square test. The statisti-
cian was blinded to the nature of the treatment groups coded
as A, B, and C.
The sample size calculation was performed considering
30% reduction in CRBD with medications with type I error
rate of 5% and type II error rate of 10%. The size of the
control group was chosen 1.4 times the size of each inter-
vention arm. As a result, 48 samples were calculated for each
intervention arm and finally 50 samples were chosen re-
garding the possibility of attrition. As a result, 50 samples in
each intervention arm (groups T and G) and 70 samples for
the control group (group P) were enrolled.
The ethics of this study has been approved by the ethics
committee of the Iran University of Medical Sciences with
the approval code of IR.IUMS.REC1395.9221254002 and
were in accordance with the 1964 Declaration of Helsinki and
its later amendments. All patients were explained about the
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study protocol in their own language. Written informed
consent was obtained.
This study has been registered at the Iranian Registry
of Clinical Trials with the registration number of
IRCT201204066504N3.
Results
During the study period, 249 patients were assessed for
eligibility. Ten patients were excluded for age >60 years,
5 patients for chronic use of pain medication, 24 patients
for lower urinary tract symptoms, 3 patients for history of
transurethral resection of prostate, 4 patients for history of
lower urinary tract surgery/instrumentation, 6 patients for
probable overactive bladder or neurogenic bladder, 15 pa-
tients for diabetes mellitus, and 12 patients refused to par-
ticipate. Fifty patients were enrolled in each treatment groups
of T and G, and 70 patients were enrolled in the placebo
group. Details of patients’ enrollment algorithm are outlined
in Figure 1.
Details of patients’ demographic data and operations
characteristics are presented in Table 1.
Figure 2 illustrates the confidence interval for visual ana-
log pain scores measured after PCNL separately for the three
FIG. 1. Patients’ flow dia-
gram.
Table 1. Patients’ Demographic Data and Operations’ Characteristics
Variables Group T Group G Group P p
Age, years; mean –SD 44.4 – 9.7 39.4– 10.0 44.1 – 12.2 0.03
Body mass index; mean – SD 25.9 – 3.1 25.5– 3.1 25.0 – 4.2 0.38
Stone size, mm; mean – SD 36.2 – 10.7 35.8– 9.9 37.3 – 11.8 0.74
Preop creatinine, mg/dL; mean – SD 1.2 – 0.2 1.2 – 0.2 1.3 – 0.4 0.23
Operation duration, min; mean – SD 97.9 – 19.7 98.3– 26.8 105.9– 23.4 0.10
PCNL history; n (%) 8 (16) 8 (16) 12 (17) 0.99
Double-J history; n (%) 12 (24) 7 (14) 13 (19) 0.41
SWL history; n (%) 12 (24) 17 (34) 20 (29) 0.58
2 tract PCNL; n (%) 13 (26) 12 (24) 18 (26) 0.97
Double-J insertion; n (%) 42 (84) 34 (68) 52 (74) 0.17
External ureteral catheter insertion; n (%) 8 (16) 16 (32) 18 (26) 0.17
Rescue pethidine injections; mean – SD 0.42 – 0.54 0.68– 0.62 2.4 – 0.64 <0.001
Rescue paracetamol injections; mean– SD 1.8 – 0.8 1.8 – 0.7 3.6 – 0.7 <0.001
PCNL= percutaneous nephrolithotomy; SWL = extracorporeal shockwave lithotripsy.
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intervention and control groups. As evident, the difference
in VAS is highest between treatment groups and the con-
trol group 1 hour after surgery. The magnitude of difference
ameliorates toward 24 hours after surgery when patients in the
placebo group still experienced higher average pain scores in
relation to treatment groups of T and G.
The numbers of patients in each category of mild, mod-
erate, and severe pain separately for the 1st, 3rd, 12th, and
24th postoperative hours are presented in Table 2. Moderate
and severe pain were experienced in 24%, 20%, and 76% of
patients in groups T, G, and P, respectively, during the first
postoperative hour. These frequencies decreased to 12%, 8%,
and 63% 12 hours after surgery. The relative frequencies of
moderate-to-severe CRBD increased slightly to 24% and
20% in the intervention groups (T and G), while it continued
to decrease to 59% in the placebo group (Fig. 2 and Table 2).
Multivariable repeated measures design was used to in-
vestigate the independent factors that had an influence on
pain perception after surgery. Age, body mass index, stone
size, number of tracts, operation duration, history of PCNL
surgery or extracorporeal shockwave lithotripsy, and inser-
tion of Double-J or ureteral catheter were not statistically
significant predictors of CRBD. Only history of Double-J
insertion was a statistically significant predictor of postop-
erative CRBD (P= 0.002).
Figure 3 illustrates that pain perception in patients with a
history of Double-J insertion was lower in comparison with
patients without such a history. This reduction in pain per-
ception was observed in all study groups, including the
control group.
Discussion
The results of this study reveal that preoperative oral
administration of tolterodine 2mg or gabapentin 600mg
significantly reduces postoperative CRBD in patients who
undergo PCNL. This reduction in CRBD was evident as
much as 24 hours after surgery when our last measurement
was made. Interestingly insertion of Double-J vs external
ureteral catheter has no statistically significant influence
on postoperative CRBD. However, history of Double-J
insertion ameliorated CRBD in all study groups probably
due to their previous experience of the symptoms. As in-
dicated previously, no previous study has compared drugs
of different classifications in reducing postoperative
CRBD specifically an antimuscarinic agent with an anti-
epileptic agent.
The influence of various medications on postoperative
CRBD has been the subject of several previous studies.
Various medications, including antimuscarinic agents, anti-
epileptic agents, anesthetics, and analgesics, have been used
to treat postoperative CRBD. In most studies, the efficacy of
administration of medications on postoperative CRBD has
been confirmed.
FIG. 2. VAS scores in different
treatment groups in postoperative
hours. (Dash-dot indicates the placebo
group, solid line indicates the tolter-
odine group, and dotted line indicates
the gabapentin group). VAS = visual
analog pain scale.
Table 2. The Severity of Catheter Related
Bladder Discomfort in Postoperative Hours
Separately in Treatment Groups
Time
(hour)
CRBD
severity
Group
Ta
Group
Ga
Group
Pa p
1 Mild 38 40 17 <0.001
Moderate 10 8 20
Severe 2 2 33
3 Mild 45 45 26 <0.001
Moderate 4 3 19
Severe 1 2 25
12 Mild 44 46 26 <0.001
Moderate 4 4 34
Severe 2 0 10
24 Mild 38 40 29 <0.001
Moderate 9 9 37
Severe 3 1 4
aData are presented as number of patients in each category.
CRBD = catheter related bladder discomfort.
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Zhang and colleagues8 in a randomized prospective trial
evaluated the influence of preoperative and postoperative
administration of solifenacin 5mg orally (PO) for 2 weeks on
postoperative CRBD in transurethral resection of bladder tu-
mor (TURT) patients. They reported 26% reduction in CRBD
in the intervention group 6 to 12 hours after the operation
which reduced to 15% at 48 to 72 hours of the surgery.
Agarwal and colleagues2 in a randomized double-blind
trial compared the administration of oxybutynin 5mg PO vs
tolterodine 2mg PO vs placebo 1 hour before surgery on
CRBD. They reported 23% to 25% reduction in CRBD in the
intervention groups in cost of more drymouth (46–51% in the
intervention group vs 19% in the placebo group).
Bala and associates5 compared the preoperative adminis-
tration of gabapentin 1200mg PO (G1) vs gabapentin 600mg
PO (G2) vs placebo on postoperative CRBD after TURT
surgery in a randomized clinical trial. They reported 0% to
26% CRBD in the G1 group vs 9% to 66% in the G2 group vs
66% to 90% in the placebo group ( p< 0.05).
Similarly, Agarwal and colleagues13 randomized 108 pa-
tients undergoing elective PCNL to gabapentin 600mg PO
and placebo. They reported severe CRBD in 1 and 2 hours
after surgery in 0% and 3% vs 42% and 25% in the gabapentin
and placebo groups, respectively.
In all cited studies, the efficacy of administration of a drug
or different doses of the same drug or the efficacies of dif-
ferent drugs within the same drug classification on CRBD has
been demonstrated. To our best knowledge, no study has
compared the efficacies of drugs of different classifications in
postoperative CRBD.
A systematic review on the management of CRBD in
elective surgeries emphasizes that wise selection between
different treatment options necessitates direct comparative
studies on their efficiencies.14
We observed statistically significant decrease in postop-
erative CRBD in patients who received oral tolterodine or
gabapentin before operation in line with prior publications.
The need for rescue medications, including intravenous an-
algesics and opioids, was markedly less in treatment groups
in comparison with the placebo group. Interestingly the dif-
ference in postoperative CRBD was not statistically signifi-
cant between treatment groups of tolterodine vs gabapentin.
Gabapentin as explained earlier in the Introduction section
is both a centrally and peripherally acting medication. Tol-
terodine on the contrary is a peripherally acting medica-
tion, which inhibits bladder muscarinic receptors. The pain
of CRBD is medicated through bladder pathways; however,
the pain of PCNL is mediated through kidney receptors which
should theoretically be unresponsive to tolterodine. The re-
sult of our study clearly demonstrated the equivalency of
CRBD suppression by tolterodine in comparison with gaba-
pentin. Unfortunately, we did not assess postoperative PCNL
pain; however, theoretically gabapentin can be more effec-
tive on the perception of postoperative PCNL pain due to its
central effects. Therefore, one can conclude that gabapentin
will result in more overall suppression of CRBD and post-
operative PCNL pain in comparison with tolterodine al-
though this conclusion cannot be directly extracted from our
crude data but can be the subject of future studies.
Another interesting finding was that the reduction in per-
ception of CRBD was maintained as much as 24 hours after
oral administration of tolterodine or gabapentin when our last
VAS measurement was performed. Studies which evaluated
the preoperative oral administration of an antimuscarinic
agent or an antiepileptic agent on postoperative CRBD eval-
uated CRBD as much as 6 hours after surgery.2–4,6,7,9,10,12,13
No study with only a single oral preoperative administration
of medication has evaluated CRBD beyond 6 hours after
FIG. 3. VAS scores in
different treatment groups in
postoperative hours sepa-
rately for patients with and
without history of Double-J
insertion. (Dash-dot indi-
cates the placebo group,
solid line indicates the tol-
terodine group, and dotted
line indicates the gabapentin
group.)
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administration when theoretically the medical influence of
medications like gabapentin which need every 6 hour ad-
ministration disappears. Nonetheless, the reduction in CRBD
perception was maintained as much as 24 hours after opera-
tion when our last measurement was made. We think that this
observation could be explained by psychologic influence of
less prior CRBD during early postoperative hours on their
later reporting of CRBD; however, we have no hard proof for
our claim.
Shariat and coworkers4 investigated the influence of intra-
venous administration of ketamine after induction of anesthe-
sia on postoperative CRBD. They reported that postoperative
difference on CRBDwas only observed 1 hour after operation.
Two and 6 hours after the operation the CRBD perception in
treatment groups was not statistically different. On the con-
trary, most other studies which evaluated preoperative oral
administration of antimuscarinic, antiepileptic, anesthetic, or
analgesic agents on postoperative CRBD, reported the main-
tenance of influence as much as 6 hours after surgery when
their last measurements were made.2,3,6,7,10,12,13,21
Another interesting finding of this study was the signifi-
cantly reduced CRBD perception in patients with history
of Double-J insertion in all treatment groups. We could not
find evidence for investigation of such relationship in prior
studies.22,23
The limitations of this study include failure to simulta-
neously investigate the influence of combined administration
of tolterodine and gabapentin. As a marked percentage of
patients in each treatment group experienced postoperative
CRBD despite oral medication, it is advisable to study the
combined efficacy of an antimuscarinic agent with an anti-
epileptic to observe their combined efficacy on CRBD re-
garding the safety profile of their administration with regard
to absence of deleterious side effects in all published studies.
We cannot exclude the possibility of misperception of pa-
tients’ subjective assessment of CRBD by VAS from the
overall postoperative PCNL pain; however, the location of
PCNL pain is away from CRBD which is felt suprapubic or
over the urethra, and the results of our study support the
observation that medications with only possible effect on
CRBD (tolterodine) suppressed CRBD pain equivalently to
centrally and peripherally acting medications like gaba-
pentin. VAS has not been standardized for measuring CRBD
discomfort. We also failed to observe for side effects of
prescribed medications; however, several previous studies
reported the frequency of medication side effects and most
agreed that side effects however frequent are tolerable.14
Conclusions
The results of this study approve the efficacy of preoperative
oral administration of tolterodine 2mg or gabapentin 600mg
1 hour before surgery on CRBD during the first 24 hours after
surgery in patients who undergo PCNL. The need for rescue
analgesic or opioid to relieve CRBD is markedly less in pa-
tients premeditated with the above drugs. In patients with a
history ofDouble-J insertion, the perception of CRBD is less in
comparison with patients without such a history.
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CRBD¼ catheter related bladder discomfort
PCNL¼ percutaneous nephrolithotomy
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